3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

NCT02057445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkins Lymphoma
Hodgkins Lymphoma
Lymphoproliferative Disorder

Interventions

DRUG: EBV CTL's
OTHER: Peripheral Blood Donor

Sponsor

New York Medical College

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]